Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

被引：17
|
作者：
Mann, Johannes F. E. [1 ,2 ]
Muskiet, Marcel H. A. [3 ]
机构：
[1] KfH Kidney Ctr, 15 Isoldenst, D-80804 Munich, Germany
[2] Friedrich Alexander Univ, Univ Hosp, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Vrije Univ, Amsterdam Univ, Med Ctr, Dept Internal Med,Diabet Ctr, Amsterdam, Netherlands
来源：
KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期
关键词：
RENAL OUTCOMES; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE;
D O I：
10.1016/j.kint.2020.08.036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：314 / 318
页数：5
相关论文
共 50 条
  • [41] GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
    Isabel del Olmo-Garcia, Maria
    Francisco Merino-Torres, Juan
    JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [42] An update on DPP-4 inhibitors in the management of type 2 diabetes
    Cahn, Avivit
    Cernea, Simona
    Raz, Itamar
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (04) : 409 - 419
  • [43] GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
    Monney, Marine
    Jornayvaz, Francois R.
    Gariani, Karim
    DIABETES & METABOLISM, 2023, 49 (05)
  • [44] Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Roumeliotis, Stefanos
    Leivaditis, Konstantinos
    Eleftheriadis, Theodoros
    Liakopoulos, Vassilios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [45] Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists
    Goldenberg, Ronald M.
    Gilbert, Jeremy D.
    Manjoo, Priya
    Pedersen, Sue D.
    Woo, Vincent C.
    Lovshin, Julie A.
    OBESITY REVIEWS, 2024, 25 (03)
  • [46] Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer, Milton
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (05) : 461 - 463
  • [47] Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 773 - 777
  • [48] The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
    von Scholten, Bernt Johan
    Kreiner, Frederik Flindt
    Rasmussen, Soren
    Rossing, Peter
    Idorn, Thomas
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [49] Management of Type 2 Diabetes Mellitus with Overweight: Focus on SGLT-2 Inhibitors and GLP-1 Receptor Agonists
    Jargin, Sergei V.
    EUROPEAN JOURNAL OF THERAPEUTICS, 2019, 25 (02): : 93 - 96
  • [50] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
12345